Rafael Pharmaceuticals Announces Expansion into South Korea of Pivotal Phase 3 Trial of CPI-613® (devimistat) in Patients with Metastatic Pancreatic Cancer

NEXT STORY
Beroni Group to Launch its Advanced US FDA-Approved Virus Diagnostic Kit to Help Combat Global Outbreaks of Zika, Dengue, Chikungunya and West Nile Viruses
PREV STORY
Zai Lab Partner, GSK, Announces U.S. Food and Drug Administration Approval of Additional Indication for Zejula (niraparib) for Late-line Treatment for Women with Recurrent Ovarian Cancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Sensus Healthcare Reports Second Quarter 2020 Financial Results

author_avatar
NASDAQ Market News

Onconova Therapeutics Announces that the Required Number of Survival Events Has Been Reached for the Pivotal Phase 3 INSPIRE Trial Data Analysis

author_avatar
NASDAQ Market News

Qu Biologics Files Important New IP for the Treatment of Post-Surgical Immune Dysfunction and Prevention of Cancer Metastasis

author_avatar
NASDAQ Market News